Faris Shweikeh, MD1, Abdur Rahman Jabir, MD2, Madison Simons, PhD3, Samita Garg, MD4, Michael Cline, DO4, Scott Gabbard, MD4, Matthew Hoscheit, MD4, Anthony J. Lembo, MD5 1Cleveland Clinic Akron General, Akron, OH; 2Wake Forest Baptist Medical Center, Winston-Salem, NC; 3Cleveland Clinic, Cleveland, OH; 4Cleveland Clinic Foundation, Cleveland, OH; 5Digestive Disease Institute, Cleveland Clinic, Cleveland, OH
Introduction: CVS is a poorly understood disorder of gut-brain interaction (DGBI) characterized by recurring episodes of intractable nausea and vomiting. The aim of this study was to assess clinical, economic, and epidemiological characteristics of hospitalized patients in the United States with Cyclic Vomiting Syndrome (CVS).
Methods: The study utilized the Healthcare Cost and Utilization Project’s National Inpatient Sample between 2016-2019. Chi-square test and logistic regression were performed to compare the variables. All analyses included sample weights, strata, and clusters to account for the complex survey design.
Results: Admission rates declined from 11,055 in 2016 to 8,625 in 2019. Mean age (34.7 years), females (62.5%), and racial distribution (61.8% White) remained stable. Patients were more likely to be 18-30 years old (37.2%) and female (62.5%). Comorbidities included anxiety/depression (38.6%) and cannabis use (35.0%). Overall, 90.4% were discharged routinely (i.e. to home). Older age (p=0.002) and female gender (p< 0.001) had higher length of stay (LOS) and charges. Hispanics incurred higher costs (p< 0.001). Depression/anxiety comorbidity (p< 0.001) and teaching hospitals (p< 0.001) were associated with significantly higher LOS and cost.
Discussion: The number of hospitalizations declined between 2016 and 2019, with the latter having 8,625 hospitalizations costing over $300 million. Young females represent a larger group, African Americans were disproportionally affected, and Hispanics had the highest hospitalization costs. Anxiety and depression are primary comorbidities. The disparities identified can help clinicians identify riskier CVS patients who may become a burden on the healthcare system, stratifying them for closer monitoring with the goal of improved outcomes.
Disclosures:
Faris Shweikeh indicated no relevant financial relationships.
Abdur Rahman Jabir indicated no relevant financial relationships.
Madison Simons indicated no relevant financial relationships.
Samita Garg indicated no relevant financial relationships.
Michael Cline indicated no relevant financial relationships.
Scott Gabbard indicated no relevant financial relationships.
Matthew Hoscheit indicated no relevant financial relationships.
Anthony Lembo: Allurion – Stock Options. Bristol Myers Squibb – Stock Options. Johnson & Johnson – Stock Options. Vibrant Advisory Board – Advisory Committee/Board Member.
Faris Shweikeh, MD1, Abdur Rahman Jabir, MD2, Madison Simons, PhD3, Samita Garg, MD4, Michael Cline, DO4, Scott Gabbard, MD4, Matthew Hoscheit, MD4, Anthony J. Lembo, MD5. P4044 - Recent Findings on Clinical and Economic Outcomes of Cyclic Vomiting Syndrome: An Analysis of the National Inpatient Database, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.
